Previous Close | 0.3697 |
Open | 0.3700 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.3502 - 0.3870 |
52 Week Range | 0.0400 - 0.3870 |
Volume | |
Avg. Volume | 361,349 |
Market Cap | 37.823M |
Beta (5Y Monthly) | -3.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the United States Patent and Trademark Office (the "USPTO") has issued a Notice of Allowance for claims related to the Company's lead candidate Pritumumab.
VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the completion of the Third cohort in dosing patients for its Phase I trial for Brain Cancer.
VERO BEACH, FL / ACCESSWIRE / May 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO, Sean Carrick, was recently interviewed by Proactive Investors (ProactiveInvestors.